The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Alynlam Pharmaceuticals; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; Incyte; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO; Loxo
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Moh'd M. Khushman
Stock and Other Ownership Interests - Cardiff Oncology
Consulting or Advisory Role - Cardinal Health; Muerus; TriSalus Life Sciences
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbvie (Inst); FOGPharma (Inst); IgM Biosciences (Inst); Torl Biotherapeutics (Inst)
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; Black Canyon Bio; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Agastiya Biotech; Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics; Incyte; Mirati Therapeutics; Novelty Nobility; Processa Pharmaceuticals, Inc; Rappta Therapeutics; Stemline Therapeutics
Research Funding - AADi; Adagene (Inst); Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Nimbus Therapeutics (Inst); Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Agenus; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Regeneron; Seagen; Taiho Oncology
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; BPGBio; Cadila Pharmaceuticals (I); EcoR1 Capital; Genome Insight; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Gilead Sciences (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Minjung Choi
Employment - Fog Pharmaceuticals; Moderna Therapeutics (I)
Stock and Other Ownership Interests - Fog Pharmaceuticals; Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - Moderna Therapeutics (I)
 
Lalith V Akella
Employment - Fog Pharmaceuticals
Stock and Other Ownership Interests - Calithera Biosciences; Fog Pharmaceuticals
 
Amanda Garofalo
Employment - Fog Pharmaceuticals
Stock and Other Ownership Interests - Arcus Biosciences; Fog Pharmaceuticals; Kymera
Research Funding - Fog Pharmaceuticals
 
Ziyang Yu
Employment - Fog Pharmaceuticals
Stock and Other Ownership Interests - Fog Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Acetylon Pharmaceuticals (I); Constellation Pharmaceuticals; Radius Health
 
Varsha Iyer
Employment - Agios; Fog Pharmaceuticals
Stock and Other Ownership Interests - Agios; Fog Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Agios
 
Marie Huong Nguyen
Employment - Bristol Myers Squibb Foundation; Fog Pharmaceuticals
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Keith W. Orford
Employment - Fog Pharmaceuticals
Leadership - Fog Pharmaceuticals
Stock and Other Ownership Interests - Fog Pharmaceuticals
 
Samuel J. Klempner
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Exact Sciences; I-Mab; Merck; Mersana; Novartis; Sanofi/Aventis; SERVIER
Research Funding - Arcus Biosciences (Inst); BeiGene (Inst); Leap Therapeutics (Inst); Silverback Therapeutics (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice